sorafenib has been researched along with cabozantinib in 59 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (cabozantinib) | Trials (cabozantinib) | Recent Studies (post-2010) (cabozantinib) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 731 | 127 | 716 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 34 (57.63) | 24.3611 |
| 2020's | 25 (42.37) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Song, M | 2 |
| Guo, M; He, J; Jiang, X; Jiang, Y; Li, J; Liu, J; Ouyang, L; Wang, J; Zhang, J; Zhang, S | 1 |
| Chen, K; Huang, SZ; Jiang, XJ; Li, LL; Li, WM; Li, YS; Luo, YF; Wang, YL; Wei, YQ; Xiang, R; Yan, HX; Yang, J; Yang, QY; Yang, SY; Yang, W; Zhang, G; Zhu, JQ | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Acharya, B; Frett, B; Garcia, NG; Lakkaniga, NR; Ryan, KR; Saha, D; Smith, EL | 1 |
| Takami, HE | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Atkins, J; Busaidy, N; Fu, S; Hong, D; Kurzrock, R; Naing, A; Sherman, S; Wheler, J | 1 |
| Chen, W; Chen, Y; Deng, DY; Ren, M; Shang, C; Wang, J; Xiang, Q; Zhang, H; Zhang, L | 1 |
| Colao, A; Faggiano, A; Marotta, V; Sciammarella, C; Vitale, M | 1 |
| Ball, DW; Byrd, D; Dickson, P; Duh, QY; Ehya, H; Haddad, RI; Haymart, M; Hoffmann, KG; Hoh, C; Hughes, M; Hunt, JP; Iagaru, A; Kandeel, F; Kopp, P; Lamonica, DM; Lydiatt, WM; McCaffrey, J; Moley, JF; Parks, L; Raeburn, CD; Ridge, JA; Ringel, MD; Scheri, RP; Shah, JP; Sherman, SI; Sturgeon, C; Tuttle, RM; Waguespack, SG; Wang, TN; Wirth, LJ | 1 |
| Liu, J; Zhang, B; Zhang, X; Zhou, T | 1 |
| Chen, L; Dong, Q; Liu, M; Ruan, M | 1 |
| Covell, LL; Ganti, AK | 1 |
| Keck, B; Lieb, V; Lüdecke, G; Sikic, D | 1 |
| Calvo, E; Escudier, B; Grünwald, V; Heng, DY; Schmidinger, M | 1 |
| Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A | 1 |
| Bonsignore, R; Gentile, C; Lauria, A; Martorana, A | 1 |
| Braiteh, F; Burris, H; Cohn, AL; Foster, P; Kelley, RK; Lee, Y; Spira, A; Su, WC; Van Cutsem, E; Verslype, C; Vogelzang, N; Yang, TS | 1 |
| Amzal, B; Fu, S; Karcher, H; Lister, J; Meng, J | 1 |
| Gandhi, S; George, S; Jain, RK | 1 |
| He, HL; Yao, WX | 1 |
| Peck-Radosavljevic, M; Pinter, M | 1 |
| Finn, RS; Llovet, JM; Montal, R; Sia, D | 1 |
| Benevento, F; De Lorenzo, S; Granito, A; Ielasi, L; Sansone, V; Tovoli, F | 1 |
| Bouattour, M; Hulin, A; Stocco, J | 1 |
| Aguiar, PN; Chavarri-Guerra, Y; Cordón, ML; Lopes, GL; Soto-Perez-de-Celis, E | 1 |
| Personeni, N; Pressiani, T; Rimassa, L | 1 |
| Li, Z; Zhu, JY | 1 |
| Cheng, SQ; Davidson, JC; Lau, WY; Lu, J; Madoff, DC; Qi, X; Teng, GJ; Zhang, XP; Zhong, BY | 1 |
| Danilova, L; Fertig, EJ; Jafarnejad, M; Mirando, AC; Pandey, NB; Popel, AS; Sové, RJ; Tran, PT; Yarchoan, M; Zhang, Y | 1 |
| Chapel, S; Lacy, S; Nguyen, L; Tran, BD | 1 |
| Li, Q; Li, Y; Liang, R; Lin, Y; Liu, Z; Luo, M; Ye, J; Zhang, J; Zhang, Y | 1 |
| Bangaru, S; Marrero, JA; Singal, AG | 1 |
| Faivre, S; Finn, RS; Rimassa, L | 1 |
| Crucitta, S; Danesi, R; Del Re, M; Fogli, S; Gianfilippo, G; Porta, C; Rini, BI; Schmidinger, M | 1 |
| Arefian, H; Hartmann, M; Settmacher, U; Sieg, M | 1 |
| Batuyong, E; Cheung, WY; Davies, J; Fung, AS; Knox, JJ; Ko, YJ; Lee-Ying, R; Meyers, DE; Samawi, H; Sim, HW; Tam, VC; Zaborska, V | 1 |
| Cadenas, M; Chapresto-Garzón, R; Gómez-Bravo, MA; Muntané, J; Navarro-Villarán, E; Negrete, M; Padillo, FJ; Rodríguez-Hernández, MA; Victor, VM | 1 |
| Abou-Alfa, GK; Blanc, JF; Cheng, AL; Daniele, B; Guerra, I; Kelley, RK; Marteau, F; Mollon, P; Valcheva, V; Yau, T | 1 |
| Hinrichs, JB; Kirstein, MM; Manns, MP; Marwede, T; Pinter, M; Scheiner, B; Semmler, G; Vogel, A; Voigtländer, T; Wacker, F; Wolf, C | 1 |
| Benzaghou, F; Cheng, AL; Hazra, S; Kelley, RK; Rimassa, L; W Oliver, J; Yau, T | 1 |
| Abou-Alfa, GK; Baron, AD; Bolondi, L; Cattan, S; Chan, SL; Cheng, AL; El-Khoueiry, AB; Kelley, RK; Knox, J; Lim, HY; Lougheed, JC; Merle, P; Meyer, T; Milwee, S; Park, JW; Parnis, F; Ryoo, BY; Yau, T | 1 |
| Card, PB; Knox, JJ; Lim, H; Liu, D; Meyers, BM; Ramjeesingh, R; Tam, VC | 1 |
| Bruix, J; da Fonseca, LG; Reig, M | 1 |
| Dáša, S; Igor, A; Ján, T; Jana, V | 1 |
| Achira, M; Aikata, H; Furuse, J; Hagihara, A; Ikeda, M; Inaba, Y; Kato, N; Kimura, A; Kondo, S; Kudo, M; Kuroda, S; Morimoto, M; Motomura, K; Numata, K; Tsuchiya, K | 1 |
| Bang, Y; Burgio, V; Casadei-Gardini, A; Cascinu, S; Catanese, S; Cucchetti, A; Kim, HD; Lonardi, S; Masi, G; Pellino, A; Rimassa, L; Rimini, M; Rizzato, MD; Ryoo, BY; Ryu, MH; Salani, F; Vivaldi, C; Yoo, C | 1 |
| Daniele, B; Li, Y; Lim, HY; Marteau, F; Martín, L; Mollon, P; Piscaglia, F; Sarker, D; Trojan, J; Venerito, M; Xu, Q; Zaucha, R | 1 |
| Chen, J; Wang, J; Xie, F | 1 |
| Calvisi, DF; Chen, X; Evert, M; O'Farrell, M; Roessler, S; Shang, R; Stahl, A; Sticht, C; Wang, H; Wang, X; Xu, H; Zeng, Y; Zhang, Y; Zhou, Y | 1 |
| Altayar, O; Estfan, B; Falck-Ytter, Y; O'Shea, R; Shah, R; Su, GL; Sultan, S; Wenzell, C | 1 |
| Altayar, O; Chang, CY; Falck-Ytter, Y; Muir, AJ; Shah, R | 1 |
| Antonuzzo, L; Basso, U; Bersanelli, M; Bimbatti, D; Buti, S; Carella, C; Conca, R; De Giorgi, U; Doni, L; Fornarini, G; Galli, L; Gambale, E; Giorgione, R; Naglieri, E; Nesi, G; Pignata, S; Procopio, G; Rebuzzi, SE; Roviello, G; Santini, D; Sbrana, A; Stellato, M | 1 |
| Banerjee, K; Benzaghou, F; Borbath, I; Breder, V; Chan, SL; Cheng, AL; Fawcett, J; Gane, E; Hazra, S; Kaseb, A; Kelley, RK; Makharadze, T; Melkadze, T; Merle, P; Qin, S; Rangel, JDG; Rimassa, L; Ryoo, BY; Sukeepaisarnjaroen, W; Verset, G; Yau, T; Zhu, AX | 1 |
| Acosta-Rivera, M; Bruix, J; Choo, SP; Cubillo Gracian, A; El-Khoueiry, AB; Eldawy, TE; Frassineti, GL; He, AR; Koopmans, P; Matilla, A; Neely, J; Piscaglia, F; Sangro, B; Santoro, A; Scheffold, C; Tschaika, M; Vaccaro, GM; Yau, T; Zagonel, V | 1 |
| Alvarez-Ramirez, M; Díaz-Cedillo, F; Figueroa-Valverde, L; López-Gutierrez, T; López-Ramos, M; Mateu-Armad, MV; Rosas-Nexticapa, M | 1 |
30 review(s) available for sorafenib and cabozantinib
| Article | Year |
|---|---|
Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.
Topics: Antineoplastic Agents; Drug Discovery; Humans; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridines; Quinazolines; Quinolones; Receptors, Vascular Endothelial Growth Factor; Small Molecule Libraries | 2016 |
Recent developments in small molecule therapies for renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Discovery; Humans; Kidney; Kidney Neoplasms; Molecular Targeted Therapy; Small Molecule Libraries | 2017 |
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Development; Humans; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret | 2021 |
Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.
Topics: Anilides; Benzenesulfonates; Disease Progression; Humans; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Thyroid Neoplasms | 2011 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
The evolving field of kinase inhibitors in thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Humans; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Quinolines; Sorafenib; Thyroid Neoplasms | 2015 |
Clinical observation of liver cancer patients treated with axitinib and cabozantinib after failed sorafenib treatment: a case report and literature review.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Imidazoles; Indazoles; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Retreatment; Sorafenib; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome | 2015 |
Treatment of advanced thyroid cancer: role of molecularly targeted therapies.
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Drug Approval; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Molecular Targeted Therapy; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A | 2015 |
[Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism].
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Enzyme Inhibitors; Fatigue; Humans; Hypothyroidism; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quality of Life; Sorafenib; Sulfonamides; Sunitinib | 2016 |
Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; DNA-Binding Proteins; Everolimus; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Humans; Imidazoles; Immunologic Factors; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; MicroRNAs; Molecular Targeted Therapy; Mutation; Niacinamide; Nivolumab; Nuclear Proteins; Phenylurea Compounds; Precision Medicine; Prognosis; Pyridines; Pyrimidines; Pyrroles; Quinolines; Receptors, CCR4; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Transcription Factors; Tumor Suppressor Proteins; Ubiquitin Thiolesterase; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein | 2016 |
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Topics: Anilides; Antineoplastic Agents; Axitinib; Benzimidazoles; Bevacizumab; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Quinolines; Quinolones; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2017 |
Kinase Inhibitors in Multitargeted Cancer Therapy.
Topics: Anilides; Crizotinib; Humans; Imatinib Mesylate; Imidazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2017 |
Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.
Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Humans; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Nivolumab; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Retreatment; Sorafenib; Treatment Outcome | 2017 |
Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Sorafenib | 2017 |
A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Network Meta-Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Review article: systemic treatment of hepatocellular carcinoma.
Topics: Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Nivolumab; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Ramucirumab; Sorafenib | 2018 |
Molecular therapies and precision medicine for hepatocellular carcinoma.
Topics: Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Pyridines; Quinolines; Ramucirumab; Sorafenib | 2018 |
An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib.
Topics: Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Liver Neoplasms; Phenylurea Compounds; Pyridines; Ramucirumab; Randomized Controlled Trials as Topic; Sorafenib | 2018 |
Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma.
Topics: Aged; Aged, 80 and over; Anilides; Animals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Female; Humans; Liver Neoplasms; Male; Models, Animal; Molecular Targeted Therapy; Pharmacokinetics; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Sorafenib; Treatment Outcome | 2019 |
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib.
Topics: Anilides; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Molecular Structure; Molecular Targeted Therapy; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Retreatment; Sorafenib; Treatment Outcome | 2019 |
Hepatocellular carcinoma: Current situation and challenge.
Topics: Anilides; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Female; Humans; Liver Neoplasms; Male; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Quinolines; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome | 2019 |
Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Endovascular Procedures; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Liver Transplantation; Nivolumab; Patient Care Team; Phenylurea Compounds; Portal Vein; Pyridines; Quinolines; Radiotherapy, Adjuvant; Ramucirumab; Sorafenib; Stents; Venous Thrombosis | 2019 |
Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Topics: Anilides; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy; Phenylurea Compounds; Programmed Cell Death 1 Receptor; Pyridines; Quinolines; Ramucirumab; Sorafenib; Treatment Outcome | 2019 |
Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Humans; Immunotherapy; Liver Neoplasms; Neoplasm Staging; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Ramucirumab; Sorafenib; Therapies, Investigational | 2020 |
Molecular therapies for HCC: Looking outside the box.
Topics: Algorithms; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Nivolumab; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Ramucirumab; Sorafenib; Treatment Outcome | 2020 |
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs.
Topics: Angiogenesis Inhibitors; Anilides; Axitinib; Carcinoma, Renal Cell; Drug Interactions; Humans; Indazoles; Kidney Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib | 2020 |
Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Ramucirumab; Sorafenib; Survival Analysis; Vascular Endothelial Growth Factor A | 2021 |
Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma.
Topics: Anilides; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecular Targeted Therapy; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinolines; Sorafenib | 2020 |
Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Administration Schedule; Humans; Liver Neoplasms; Neoplasm Metastasis; Phenylurea Compounds; Pyridines; Ramucirumab; Randomized Controlled Trials as Topic; Sorafenib | 2021 |
AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Phenylurea Compounds; Pyridines; Quinolines; Ramucirumab; Retreatment; Sorafenib | 2022 |
7 trial(s) available for sorafenib and cabozantinib
| Article | Year |
|---|---|
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Disease Progression; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Quinolines; Quinolones; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome; Valproic Acid | 2013 |
Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.
Topics: Adult; Aged; Anilides; Carcinoma, Hepatocellular; Disease-Free Survival; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2017 |
Cabozantinib exposure-response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Double-Blind Method; Female; Humans; Liver Neoplasms; Male; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2019 |
Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Drug Interactions; Humans; Liver Neoplasms; Pyridines; Sorafenib | 2020 |
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Pyridines; Sorafenib; Young Adult | 2020 |
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Pyridines; Sorafenib | 2022 |
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Ipilimumab; Liver Neoplasms; Nivolumab; Sorafenib | 2023 |
22 other study(ies) available for sorafenib and cabozantinib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Kinesins; Lung Neoplasms; Models, Molecular; Protein Conformation | 2015 |
Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants.
Topics: Amines; Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Structure; Mutation; Neoplasms, Experimental; NIH 3T3 Cells; Proto-Oncogene Proteins c-ret; Structure-Activity Relationship | 2018 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
Topics: Anilides; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Liver Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-met; Pyridines; Sorafenib; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2014 |
Thyroid carcinoma, version 2.2014.
Topics: Adenocarcinoma; Anilides; Carcinoma, Neuroendocrine; Guidelines as Topic; Humans; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thyroid Neoplasms | 2014 |
Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
Topics: Anilides; Antineoplastic Agents; Apoptosis; Autoantigens; Carcinoma, Papillary; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Glucose Transporter Type 3; Humans; Iodide Peroxidase; Iron-Binding Proteins; Microfilament Proteins; Muscle Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyridines; Receptors, Thyrotropin; Signal Transduction; Sorafenib; Symporters; Thyroid Neoplasms | 2015 |
Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Decision-Making; Clinical Trials, Phase III as Topic; Computer Simulation; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Markov Chains; Models, Economic; Neoplasm Staging; Palliative Care; Patient Selection; Placebos; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Sorafenib | 2019 |
Mechanistically detailed systems biology modeling of the HGF/Met pathway in hepatocellular carcinoma.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Computer Simulation; Drug Resistance, Neoplasm; Hep G2 Cells; Hepatocyte Growth Factor; Humans; Integrins; Liver Neoplasms; Proto-Oncogene Proteins c-met; Pyridines; Signal Transduction; Sorafenib; Systems Biology | 2019 |
Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Resistance, Neoplasm; Germany; Humans; Liver Neoplasms; Markov Chains; Pyridines; Quality-Adjusted Life Years; Sorafenib; Survival Analysis; United States | 2020 |
Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Canada; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Databases, Factual; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Patient Selection; Phenylurea Compounds; Pyridines; Ramucirumab; Randomized Controlled Trials as Topic; Sorafenib; Time Factors | 2020 |
Differential effectiveness of tyrosine kinase inhibitors in 2D/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells.
Topics: Adult; Anilides; Apoptosis; Cell Culture Techniques; Cell Differentiation; Cell Proliferation; Cell Respiration; Female; Hep G2 Cells; Hepatocytes; Humans; Liver Neoplasms; Male; Mitochondria; Oxygen Consumption; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Sorafenib; Spheroids, Cellular; Tumor Suppressor Protein p53 | 2020 |
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Carcinoma, Hepatocellular; Comparative Effectiveness Research; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Outcome and Process Assessment, Health Care; Phenylurea Compounds; Progression-Free Survival; Pyridines; Randomized Controlled Trials as Topic; Sorafenib | 2020 |
Sequential systemic treatment in patients with hepatocellular carcinoma.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Nivolumab; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Ramucirumab; Sorafenib | 2020 |
Systemic treatment for hepatocellular carcinoma.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Phenylurea Compounds; Pyridines; Ramucirumab; Sorafenib | 2020 |
Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study.
Topics: Aged; Anilides; Carcinoma, Hepatocellular; Female; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Pyridines; Sorafenib | 2021 |
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis.
Topics: Adult; Aged; Anilides; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Progression-Free Survival; Pyridines; Salvage Therapy; Sorafenib | 2021 |
Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison.
Topics: Adult; alpha-Fetoproteins; Anilides; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Pyridines; Ramucirumab; Sorafenib | 2021 |
Therapeutic efficacy of FASN inhibition in preclinical models of HCC.
Topics: Anilides; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Fatty Acid Synthase, Type I; Fatty Acid Synthases; Fatty Liver; Humans; Liver; Liver Neoplasms; Mammals; Mice; Phosphoric Monoester Hydrolases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Pyridines; Sorafenib; Tensins; TOR Serine-Threonine Kinases | 2022 |
AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Phenylurea Compounds; Pyridines; Quinolines; Ramucirumab; Retreatment; Sorafenib | 2022 |
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Kidney Neoplasms; Nivolumab; Pyridines; Retrospective Studies; Sorafenib | 2022 |
Interaction of Some Amino-Nitrile Derivatives with Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) Using a Theoretical Model.
Topics: Humans; Models, Theoretical; Neoplasms; Sorafenib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2023 |